Risk assessment, diagnosis, and treatment of cancer treatment-related adrenal insufficiency

References

• Broersen LH, Pereira AM, Jorgensen JO, et al. Adrenal Insufficiency in Corticosteroids Use: systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2015 Jun;100(6):2171–2180.
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364–389.
   PubMed Web of Science ®Google Scholar
• Rushworth RL, Torpy DJ, Falhammar H. Adrenal Crisis. N Engl J Med. 2019;381(9):852–861.
   PubMed Web of Science ®Google Scholar
• Sioutos P, Yen V, Arbit E. Pituitary gland metastases. Ann Surg Oncol. 1996 Jan;3(1):94–99.
   PubMed Web of Science ®Google Scholar
• Tallis PH, Rushworth RL, Torpy DJ, et al. Adrenal insufficiency due to bilateral adrenal metastases – a systematic review and meta-analysis. Heliyon. 2019;5(5):e01783.
   PubMed Web of Science ®Google Scholar
• Javanbakht A, D’Apuzzo M, Badie B, et al. Pituitary metastasis: a rare condition. Endocr Connect. 2018;7(10):1049–1057.
   Web of Science ®Google Scholar
• Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013 Apr;98(4):1361–1375.
   PubMed Web of Science ®Google Scholar
• Ohara N, Ohashi K, Fujisaki T, et al. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: a Case Report and Literature Review. Intern Med. 2018 Feb 15;57(4):527–535.
   PubMed Web of Science ®Google Scholar
• Grossman AB. The Diagnosis and Management of Central Hypoadrenalism. J Clin Endocrinol Metab. 2010;95(11):4855–4863.
   PubMed Web of Science ®Google Scholar
• Workeneh BT, Jhaveri KD, Rondon-Berrios H. Hyponatremia in the cancer patient. Kidney Int. 2020 Oct;98(4):870–882.
   PubMed Web of Science ®Google Scholar
• Johnson EO, Calogero AE, Konstandi M, et al. Effects of experimentally induced hyperthyroidism on central hypothalamic–pituitary–adrenal axis function in rats: in vitro and in situ studies. Pituitary. 2013;16(2):275–286.
   PubMed Web of Science ®Google Scholar
• Brown S, Hadlow N, Badshah I, et al. A time-adjusted cortisol cut-off can reduce referral rate for Synacthen stimulation test whilst maintaining diagnostic performance. Clin Endocrinol (Oxf). 2017;87(5):418–424.
   PubMed Web of Science ®Google Scholar
• Kebebew E. Adrenal Incidentaloma. N Engl J Med. 2021;384(16):1542–1551.
   PubMed Web of Science ®Google Scholar
• Herndon J, Nadeau AM, Davidge-Pitts CJ, et al. Primary adrenal insufficiency due to bilateral infiltrative disease. Endocrine. 2018 Dec;62(3):721–728.
   PubMed Web of Science ®Google Scholar
• Hodgson A, Pakbaz S, Mete O. A Diagnostic Approach to Adrenocortical Tumors. Surg Pathol Clin. 2019 Dec;12(4):967–995.
   PubMedGoogle Scholar
• Rushworth RL, Torpy DJ, Falhammar H. Adrenal crises: perspectives and research directions. Endocrine. 2017;55(2):336–345.
   PubMed Web of Science ®Google Scholar
• Lubomski A, Falhammar H, Torpy DJ, et al. The epidemiology of primary and secondary adrenal malignancies and associated adrenal insufficiency in hospitalised patients: an analysis of hospital admission data, NSW, Australia. BMC Endocr Disord. 2021;21(1). https://doi.org/10.1186/s12902-021-00787-6.
   Google Scholar
• Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: european Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1–G34.
   PubMed Web of Science ®Google Scholar
• Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma.Analysis of 1000 autopsied cases. Cancer. 1950;3(1):74–85.
   PubMed Web of Science ®Google Scholar
• Wagnerova H, Lazurova I, Felsoci M. Adrenal metastases. Bratisl Lek Listy. 2013;114(4):237–240.
   PubMed Web of Science ®Google Scholar
• Sahagian-Edwards A, Holland JF. Metastatic carcinoma to the adrenal glands with cortical hypofunction. Cancer. 1954 Nov;7(6):1242–1245.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Fisher SI. Primary adrenal lymphoma: a systematic review. Ann Hematol. 2013 Dec;92(12):1583–1593.
   PubMed Web of Science ®Google Scholar
• Gamelin E, Beldent V, Rousselet MC, et al. Non-Hodgkin’s lymphoma presenting with primary adrenal insufficiency. A disease with an underestimated frequency? Cancer. 1992 May 1;69(9):2333–2336.
   PubMed Web of Science ®Google Scholar
• Mao JJ, Dages KN, Suresh M, et al. Presentation, disease progression and outcomes of adrenal gland metastases. Clin Endocrinol (Oxf). 2020 Nov;93(5):546–554.
   PubMed Web of Science ®Google Scholar
• Teears RJ, Silverman EM. Clinicopathologic review of 88 cases of carcinoma metastatic to the pituitary gland. Cancer. 1975;36(1):216–220.
   PubMed Web of Science ®Google Scholar
• Komninos J, Vlassopoulou V, Protopapa D, et al. Tumors Metastatic to the Pituitary Gland: case Report and Literature Review. J Clin Endocrinol Metab. 2004;89(2):574–580.
   PubMed Web of Science ®Google Scholar
• McCormick PC, Post KD, Kandji AD, et al. Metastatic Carcinoma to the Pituitary Gland. Br J Neurosurg. 1989;3(1):71–79.
   PubMedGoogle Scholar
• Ach T, Wojewoda P, Toullet F, et al. Multiple endocrinological failures as a clinical presentation of a metastatic lung adenocarcinoma. Endocrinol Diabetes Metab Case Rep. 2020;2020(1):20–0024.
   Google Scholar
• Patel KR, Zheng J, Tabar V, et al. Extended Survival After Surgical Resection for Pituitary Metastases: clinical Features, Management, and Outcomes of Metastatic Disease to the Sella. Oncologist. 2020 May;25(5):e789–e797.
   PubMed Web of Science ®Google Scholar
• Li B, Cheng JH, Zhu HB, et al. Pituitary metastasis from renal cell carcinoma: case report and review of the literature. Int J Neurosci. 2021 Feb;131(2):199–205.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Yasuda J, Ashida K, et al. Masked Diabetes Insipidus Hidden by Severe Hyponatremia: a Case of Pituitary Metastasis of Lung Adenocarcinoma. Am J Case Rep. 2020 Dec 18;21:e928113.
   PubMed Web of Science ®Google Scholar
• Eaton HJ, Phillips PJ, Hanieh A, et al. Rapid onset of pituitary apoplexy after goserelin implant for prostate cancer: need for heightened awareness. Intern Med J. 2001 Jul;31(5):313–314.
   PubMed Web of Science ®Google Scholar
• Deligiannis NG, Sosa S, Danilowicz K, et al. Endocrine dysfunction induced by immune checkpoint inhibitors. Medicina (B Aires). 2021;81(2):269–278.
   PubMed Web of Science ®Google Scholar
• Hattersley R, Nana M, Lansdown AJ. Endocrine complications of immunotherapies: a review. Clin Med (Lond). 2021 Mar;21(2):e212–e222.
   PubMed Web of Science ®Google Scholar
• Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev. 2019 Feb 1;40(1):17–65.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: a Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 1;4(2):173–182.
   PubMed Web of Science ®Google Scholar
• Iglesias P, Sanchez JC, Diez JJ. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Pituitary. 2021 Aug;24(4):630–643.
   PubMed Web of Science ®Google Scholar
• Lu J, Li L, Lan Y, et al. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: a systematic review and meta-analysis. Cancer Med. 2019 Dec;8(18):7503–7515.
   PubMed Web of Science ®Google Scholar
• Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13(1):29–38.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-Induced Hypophysitis: a Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma. J Clin Endocrinol Metab. 2014;99(11):4078–4085.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation. N Engl J Med. 2015;372(4):320–330.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N Engl J Med. 2012;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Chang C-Y, Park H, Malone DC, et al. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma. JAMA Network Open. 2020;3(3):e201611.
   PubMed Web of Science ®Google Scholar
• Xing P, Zhang F, Wang G, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer. 2019;7(1):1.
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem J-E, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. JAMA Oncol. 2018;4(12):1721.
   PubMed Web of Science ®Google Scholar
• de Filette J, Andreescu CE, Cools F, et al. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res. 2019 Mar;51(3):145–156.
   PubMed Web of Science ®Google Scholar
• Lee DJ, Lee HJ, Farmer JR, et al. Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. Curr Cardiol Rep. 2021;23(8):8.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, Elia G, et al. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. Int J Mol Sci. 2019 May 24;20(10):2560.
   PubMed Web of Science ®Google Scholar
• De Sousa SM, Long GV, Tonks KT. Ipilimumab-induced hypophysitis: early Australian experience. Med J Aust. 2014 Aug 18;201(4):198–199.
   PubMed Web of Science ®Google Scholar
• Albarel F, Castinetti F, Brue T. MANAGEMENT OF ENDOCRINE DISEASE: immune check point inhibitors-induced hypophysitis. Eur J Endocrinol. 2019;181(3):R107–R118.
   PubMedGoogle Scholar
• Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: a Retrospective Cohort Study. Clin Cancer Res. 2015;21(4):749–755.
   PubMed Web of Science ®Google Scholar
• Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade. Am J Pathol. 2016;186(12):3225–3235.
   PubMed Web of Science ®Google Scholar
• Hinata Y, Ohara N, Sakurai Y, et al. Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: a Case Report and Literature Review. Am J Case Rep. 2021 Jul 15;22:e931639.
   PubMed Web of Science ®Google Scholar
• Gamulin M, Nham E, Rkman D, et al. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review. Croat Med J. 2020 Aug 31;61(4):326–332.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Ott PA, Hodi FS, et al. Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer. 2018 Mar 15;124(6):1111–1121.
   PubMed Web of Science ®Google Scholar
• Araujo PB, Coelho MC, Arruda M, et al. Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest. 2015 Nov;38(11):1159–1166.
   PubMed Web of Science ®Google Scholar
• Torino F, Barnabei A, De Vecchis L, et al. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist. 2012;17(4):525–535.
   PubMed Web of Science ®Google Scholar
• Amereller F, Deutschbein T, Joshi M, et al. Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study. Pituitary. 2021; https://doi.org/10.1007/s11102-021-01182-z.
   Google Scholar
• Nguyen H, Shah K, Waguespack SG, et al. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer. 2021;28(7):419–431.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob -J-J, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016;375(19):1845–1855.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017 May;18(5):611–622.
   PubMed Web of Science ®Google Scholar
• Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012 May;13(5):459–465.
   PubMed Web of Science ®Google Scholar
• Faje A, Reynolds K, Zubiri L, et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019;181(3):211–219.
   PubMed Web of Science ®Google Scholar
• Chapman PR, Singhal A, Gaddamanugu S, et al. Neuroimaging of the Pituitary Gland: practical Anatomy and Pathology. Radiol Clin North Am. 2020 Nov;58(6):1115–1133.
   PubMed Web of Science ®Google Scholar
• Higham CE, Olsson-Brown A, Carroll P, et al. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7(7):G1–G7.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Lambotte O, Kostine M, et al. THU0628 IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY) Annals of the Rheumatic Diseases. 2019;78:607–608.
   Web of Science ®Google Scholar
• Grouthier V, Lebrun‐Vignes B, Moey M, et al. Immune Checkpoint Inhibitor‐Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. Oncologist. 2020;25(8):696–701.
   PubMed Web of Science ®Google Scholar
• Yamagata S, Kageyama K, Takayasu S, et al. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer. Intern Med. 2019 Dec 15;58(24):3557–3562.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal Replacement in Hypopituitarism in Adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(11):3888–3921.
   PubMed Web of Science ®Google Scholar
• Elshimy G, Gandhi A, Guo R, et al. Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer. J Investig Med High Impact Case Rep. 2020;8:232470962093680.
   Web of Science ®Google Scholar
• Lodish MB. Kinase Inhibitors: adverse Effects Related to the Endocrine System. J Clin Endocrinol Metab. 2013;98(4):1333–1342.
   PubMed Web of Science ®Google Scholar
• Lodish MB, Stratakis CA. Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer. 2010;17(3):R233–R244.
   PubMed Web of Science ®Google Scholar
• Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration Drug Approval Summary: sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma. Oncologist. 2007;12(1):107–113.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Kawai K, Miyazaki J, et al. A Case of Acute Adrenal Insufficiency Unmasked During Sunitinib Treatment for Metastatic Renal Cell Carcinoma. Jpn J Clin Oncol. 2012;42(8):764–766.
   PubMed Web of Science ®Google Scholar
• Chandrashekar N, McKenney R. The Eyes Cannot See What the Mind Does Not Know: endocrinological Side Effects of Ibrutinib. Wmj. 2020 Dec;119(4):293–295.
   PubMedGoogle Scholar
• Gucalp A, Sparano JA, Caravelli J, et al. Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer. Clin Breast Cancer. 2011;11(5):306–311.
   PubMed Web of Science ®Google Scholar
• Bilgir O, Kebapcilar L, Bilgir F, et al. Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction? Int J Clin Pract. 2010 Jan;64(1):45–50.
   PubMed Web of Science ®Google Scholar
• Colombo C, De Leo S, Di Stefano M, et al. Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy. J Clin Endocrinol Metab. 2019;104(3):779–784.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N Engl J Med. 2015;372(7):621–630.
   PubMed Web of Science ®Google Scholar
• Wells Sa, Robinson BG, Gagel RF, et al. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: a Randomized, Double-Blind Phase III Trial. J clin oncol. 2012;30(2):134–141.
   PubMed Web of Science ®Google Scholar
• Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ. 2021;n1380. https://doi.org/10.1136/bmj.n1380
   Google Scholar
• Han HS, Park JC, Park SY, et al. A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: a Korean South West Oncology Group Study. Oncologist. 2015 Dec;20(12):1432–1439.
   PubMed Web of Science ®Google Scholar
• Tamura M, Yokoyama N, Nishikawa T, et al. Improvement of Hypothyroidism after Glucocorticoid Replacement in Isolated Adrenocorticotropin Deficiency. Int Med. 1995;34(6):559–563.
   PubMed Web of Science ®Google Scholar
• Whorwood CB, Sheppard MC, Stewart PM. Tissue specific effects of thyroid hormone on 11β-hydroxysteroid dehydrogenase gene expression. J Steroid Biochem Mol Biol. 1993;46(5):539–547.
   PubMed Web of Science ®Google Scholar
• Lewandowski KC, Marcinkowska M, Skowrońska-Jóźwiak E, et al. New onset Graves’ disease as a cause of an adrenal crisis in an individual with panhypopituitarism: brief report. Thyroid Res. 2008;1(1):7.
   PubMedGoogle Scholar
• Oltmanns KM, Fehm HL, Peters A. Chronic fentanyl application induces adrenocortical insufficiency. J Intern Med. 2005;257(5):478–480.
   PubMed Web of Science ®Google Scholar
• Policola C, Stokes V, Karavitaki N, et al. Adrenal insufficiency in acute oral opiate therapy. Endocrinol Diabetes Metab Case Rep. 2014;2014(1);13–0071.
   Google Scholar
• González Villarroel P, Fernández Pérez I, Páramo C, et al. Megestrol acetate-induced adrenal insufficiency. Clin Transl Oncol. 2008;10(4):235–237.
   PubMed Web of Science ®Google Scholar
• Dev R, Del Fabbro E, Bruera E. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer. 2007;110(6):1173–1177.
   PubMed Web of Science ®Google Scholar
• Kim HR, Kim JH, Rhee Y, et al. Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy. Oncology. 2016;90(5):248–254.
   PubMed Web of Science ®Google Scholar
• Luton J-P, Cerdas S, Billaud L, et al. Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane Therapy. N Engl J Med. 1990;322(17):1195–1201.
   PubMed Web of Science ®Google Scholar
• Besser GM, Jeffcoate WJ. Endocrine and metabolic diseases. Adrenal diseases. BMJ. 1976;1(6007):448–451.
   PubMedGoogle Scholar
• Bianchini M, Puliani G, Chiefari A, et al. Metabolic and Endocrine Toxicities of Mitotane: a Systematic Review. Cancers (Basel). 2021;13(19):5001.
   PubMed Web of Science ®Google Scholar
• Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res. 2000;33(10):1191–1196.
   PubMed Web of Science ®Google Scholar
• Bornstein SR. Predisposing Factors for Adrenal Insufficiency. N Engl J Med. 2009;360(22):2328–2339.
   PubMed Web of Science ®Google Scholar
• Uludag M, Aygün N, İşgör A. Surgical Indications and Techniques for Adrenalectomy. SiSli Etfal Hastanesi Tip Bulteni/The Medical Bulletin of Sisli Hospital. 2020;54(1):8–22.
   PubMed Web of Science ®Google Scholar
• Mackay D, Nordenström A, Falhammar H. Bilateral Adrenalectomy in Congenital Adrenal Hyperplasia: a Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2018;103(5):1767–1778.
   PubMed Web of Science ®Google Scholar
• Perysinakis I, Aggeli C, Kaltsas G, et al. Adrenal-sparing surgery: current concepts on a theme from the past. Hormones (Athens). 2020 Sep;19(3):317–327.
   PubMedGoogle Scholar
• Asari R. Estimated Risk of Pheochromocytoma Recurrence After Adrenal-Sparing Surgery in Patients With Multiple Endocrine Neoplasia Type 2A. Arch Surg. 2006;141(12):1199.
   PubMedGoogle Scholar
• Younus I, Gerges MM, Uribe-Cardenas R, et al. How long is the tail end of the learning curve? Results from 1000 consecutive endoscopic endonasal skull base cases following the initial 200 cases. J Neurosurg. 2021;134(3):750–760.
   Web of Science ®Google Scholar
• Martinez NL, Khanna O, Farrell CJ. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base. Chin Clin Oncol. 2020;9(6):75.
   PubMed Web of Science ®Google Scholar
• Juthani RG, Reiner AS, Patel AR, et al. Radiographic and clinical outcomes using intraoperative magnetic resonance imaging for transsphenoidal resection of pituitary adenomas. J Neurosurg. 2021;134(6):1824–1835.
   Web of Science ®Google Scholar
• El-Sibai K, Rajpal A, Al-Aridi R, et al. The impact of peri-operative dexamethasone administration on the normal hypothalamic pituitary adrenal response to major surgical procedures. Endocrine. 2017;58(1):134–142.
   PubMed Web of Science ®Google Scholar
• VanKoevering KK, Sabetsarvestani K, Sullivan SE, et al. Pituitary Dysfunction after Radiation for Anterior Skull Base Malignancies: incidence and Screening. J Neurol Surg B Skull Base. 2020 Feb;81(1):75–81.
   PubMed Web of Science ®Google Scholar
• Ratnasingam J, Karim N, Paramasivam SS, et al. Hypothalamic pituitary dysfunction amongst nasopharyngeal cancer survivors. Pituitary. 2015;18(4):448–455.
   PubMed Web of Science ®Google Scholar
• Minniti G, Flickinger J. The risk/benefit ratio of radiotherapy in pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019 Apr;33(2):101269.
   PubMed Web of Science ®Google Scholar
• Shah AH, Mahavadi AK, Morell A, et al. Salvage craniotomy for treatment-refractory symptomatic cerebral radiation necrosis. Neuro oncol Pract. 2020 Jan;7(1):94–102.
   PubMed Web of Science ®Google Scholar
• Voglhuber T, Kessel KA, Oechsner M, et al. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases. BMC Cancer. 2020 Jun 8;20(1):536.
   PubMed Web of Science ®Google Scholar
• Kazlauskaite R, Evans AT, Villabona CV, et al. Corticotropin Tests for Hypothalamic-Pituitary- Adrenal Insufficiency: a Metaanalysis. J Clin Endocrinol Metab. 2008;93(11):4245–4253.
   PubMed Web of Science ®Google Scholar
• Sbardella E, Isidori AM, Woods CP, et al. Baseline morning cortisol level as a predictor of pituitary-adrenal reserve: a comparison across three assays. Clin Endocrinol (Oxf). 2017;86(2):177–184.
   PubMed Web of Science ®Google Scholar
• Nowotny H, Ahmed SF, Bensing S, et al. Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis. Endocrine. 2021;71(3):586–594.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Arnaldi G, Boscaro M, et al. Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. J Endocrinol Invest. 2020;43(5):683–696.
   PubMed Web of Science ®Google Scholar
• Ohara N, Kobayashi M, Ohashi K, et al. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature. J Med Case Rep. 2019 Mar 26;13(1):88.
   PubMedGoogle Scholar
• Arlt W. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients. Endocr Connect. 2016;5(5):G1–G3.
   PubMed Web of Science ®Google Scholar
• Andrioli M, Giraldi FP, Cavagnini F. Isolated corticotrophin deficiency. Pituitary. 2006;9(4):289–295.
   PubMedGoogle Scholar
• Agha A, Tomlinson JW, Clark PM, et al. The Long-Term Predictive Accuracy of the Short Synacthen (Corticotropin) Stimulation Test for Assessment of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab. 2006;91(1):43–47.
   PubMed Web of Science ®Google Scholar
• Paisley AN, Rowles SV, Brandon D, et al. A Subnormal Peak Cortisol Response to Stimulation Testing Does Not Predict a Subnormal Cortisol Production Rate. J Clin Endocrinol Metab. 2009;94(5):1757–1760.
   PubMed Web of Science ®Google Scholar
• Venkatesh B, Cohen J. Hydrocortisone in Vasodilatory Shock. Crit Care Clin. 2019 Apr;35(2):263–275.
   PubMed Web of Science ®Google Scholar
• Dorin RI, Qualls CR, Torpy DJ, et al. Reversible increase in maximal cortisol secretion rate in septic shock. Crit Care Med. 2015;43(3):549–556.
   PubMed Web of Science ®Google Scholar
• Meyer EJ, Nenke MA, Rankin W, et al. Total and high-affinity corticosteroid-binding globulin depletion in septic shock is associated with mortality. Clin Endocrinol (Oxf). 2019 Jan;90(1):232–240.
   PubMed Web of Science ®Google Scholar
• Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018;378(9):809–818.
   PubMed Web of Science ®Google Scholar
• Venkatesh B, Finfer S, Cohen J, et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med. 2018;378(9):797–808.
   PubMed Web of Science ®Google Scholar
• Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020 Apr 11;395(10231):1208–1216.
   PubMed Web of Science ®Google Scholar